Posts by Jorg Dietrich, MD, PhD
-
CAR T-cell Therapy Feasible for Active Secondary CNS Lymphoma
Central nervous system involvement does not appear to be a risk factor for severe neurotoxicity with CD19-directed CAR T-cell therapy.
-
Circulating Blood Counts Predict Response, Survival in Recurrent Glioblastoma Treated with Bevacizumab
Massachusetts General Hospital researchers are the first to report that changes in eosinophil, lymphocyte and platelet counts might serve as biomarkers of clinical outcomes in patients with recurrent glioblastoma who are treated with bevacizumab.
Biography
Jorg Dietrich, MD, PhD, MBA, MMSc, FAAN, is the director of the Cancer & Neurotoxicity Clinic and Brain Repair Research Program at the Mass General Cancer Center and associate professor of Neurology at Harvard Medical School. His clinical interests are the management of patients with brain tumors and neurologic complications of cancer therapy. His research activities include clinical, translational and basic research in the fields of brain tumor biology, neurotoxicity and brain repair mechanisms. He is author of over 100 publications, including original research articles, review papers, book chapters and other scientific contributions. His work has been supported by the NIH, the American Cancer Society and the American Academy of Neurology.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
